Trademark Overview
On Wednesday, September 29, 2021, a trademark application was filed for RYSUNVY with the United States Patent and Trademark Office. The USPTO has given the RYSUNVY trademark a serial number of 97052319. The federal status of this trademark filing is ABANDONED - EXPRESS as of Monday, January 17, 2022. This trademark is owned by GlaxoSmithKline Biologicals SA. The RYSUNVY trademark is filed in the Pharmaceutical Products category with the following description:
(Based on Intent to Use) Vaccines; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations for the treatment of infectious diseases, pain, inflammation, obesity and cognitive disorders; Pharmaceutical preparations for the treatment of cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, respiratory, neurological, gastrointestinal, dermatological, psychiatric and immune system related diseases and disorders(Based on 44(d) Priority Application) Vaccines; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations for the treatment of infectious diseases, pain, inflammation, obesity and cognitive disorders; Pharmaceutical preparations for the treatment of cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, respiratory, neurological, gastrointestinal, dermatological, psychiatric and immune system related diseases and disorders
